News

Study Urges New Standards For Systemic Sclerosis Lung Transplants

New research presented at the American College of Rheumatology Annual Meeting in Boston highlights that patients with systemic sclerosis with end-stage lung disease cannot be denied lung transplantation on the premises that other extra-pulmonary factors will determine their long-term survival. Scleroderma, also known as systemic sclerosis (SSc), is an autoimmune disease…

PH Therapy Riociguat to Be Tested on Patients with dcSSc

Those in the Scleroderma community are taking note of recent news that Bayer HealthCare will be initiating a randomized, double-blind, placebo-controlled, Phase II clinical study to investigate efficacy and safety of riociguat in patients suffering from diffuse cutaneous systemic sclerosis (dcSSc), according to an announcement by the company. The study is…

UCSF Scientist Hosts Free Scleroderma Webinar on Lung Fibrosis

The University of California San Francisco (UCSF) will be hosting a free, live webinar entitled “Emerging Therapies in Pulmonary Fibrosis: Their Relevance for Scleroderma Patients,” to be conducted by the university’s Director of Biological Research for the Interstitial Lung Disease Program, Dr. Paul Wolters. It will be broadcasted on the Scleroderma…

Individualized Intervention Programs Benefit SSc Patients

A diagnosis of systemic sclerosis (SSc) can be extremely stressful for patients, and it is important that patients receive appropriate support to reduce emotional distress. Some patients may benefit from an interdisciplinary care program that incorporates physical therapy, occupational therapy, and specialized nurse care, according to a case study…